Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document
$2.2 million for cancer clinical trials.

Download PDFDownload PDF

Tuesday, 20 December 2005 05/592


A West Australian project to progress the clinical development of the experimental drug compound Coramsine®, which targets both kidney cancer and malignant melanoma, has been offered a $2.25 million grant by the Australian Government.

Australian Industry Minister, Ian Macfarlane, has announced the offer of a $2.25 million Commercial Ready grant to Perth-based Solbec Pharmaceuticals Limited.

“Commercial Ready is a $1 billion innovation program aimed at helping Australian companies get their smart ideas out of the laboratory, or even back yard, through proof-of-concept stages and then into the market,” said Mr Macfarlane.

“It’s worth noting that this particular grant will help test a drug compound, in Phase II clinical trials, which has the potential to have a real and positive impact on many, many Australian lives,” he said.

There currently exists no effective chemotherapy agent against end-stage malignant melanoma or renal cell carcinoma. But Solbec is buoyed by Coramsine’s® pre-clinical and clinical results to date.

Their research has shown encouraging evidence that Coramsine® has the potential to become a highly effective, non-invasive, anti-cancer therapy. It will use naturally-occurring agents to treat a wide range of cancers without significant side-effects.

“Australia consistently punches well above its own weight in medical and health research and Australian innovations like this promise to keep us ahead of the pack.”

“Perhaps more importantly, it’s this sort of work which could offer Australians suffering cancer relief from this insidious disease,” said Mr Macfarlane.

Solbec Pharmaceuticals Limited is committed to developing and commercialising therapies for life threatening and debilitating diseases.

Its current focus is on the treatment of cancer, in particular melanoma, renal cell carcinoma and malignant mesothelioma.

Company contact: Stephen Carter, Solbec Pharmaceuticals Ltd, 08 9446 7555

For more information on Commercial Ready and other AusIndustry programs, visit, phone the AusIndustry hotline on 13 28 46 or email CMR 05-654